ARTICLE | Company News
Applied Molecular, Chiron deal
January 7, 2002 8:00 AM UTC
AMEV will use its directed molecular evolution platform to optimize a therapeutic protein from CHIR. AMEV will receive an upfront signing fee and is eligible for milestones and royalties. ...